2025-04-27 17:38:38
Latest Post
Mahindra to acquire 58.96% stake in SML Isuzu for INR 555 crore to strengthen position in the Trucks and Buses segment
Manorama Industries Limited recommends final dividend of Rs. 0.60
Associated Alcohols & Breweries Ltd recommends dividend of Rs. 2
Avantel Ltd recommends final dividend of Rs. 0.20
Oriental Trimex Ltd opens new showroom and warehouse in Greater Noida
Stock Report
Bajaj Healthcare launches Magnesium L-Threonate in Nutraceutical Segment
Posted On : 2022-02-23 12:02:15( TIMEZONE : IST )
Bajaj Healthcare Limited, a leading manufacturer of APIs, Intermediates and Formulations, has announced that it has launched Magnesium L-Threonate in Nutraceutical segment.
Therapeutic effects of Magnesium L-Threonate: Neuroprotective agent.
Indication & Usage: Magnesium L- Threonate is a nutritional supplement used to normalize magnesium level in the body, helps to improve memory, muscle and nerve function and also aids in brain development by reversing the brain aging. It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, Attention disorder, Bipolar disorder, Parkinson's disease etc.
Advantages: Magnesium L-Threonate is used to prevent the loss of synapses and to improve the cognitive functions of the brain. Magnesium L- Threonate increases the magnesium ion concentration in the brain better than Magnesium Sulphate. It helps to improve long term and short-term memory loss. It is useful in the formation of new nerve cells and synapses in brain and stimulates the neuronto-neuron communication. Magnesium L- Threonate readily crosses the blood brain barrier and support healthy magnesium level.
Available dosage form: Capsules for oral administration.
Strength: 500 mgs (for Capsules).
Market size: The addressable market size is approximately INR 1500 million.
Commenting on the launch of Magnesium L-Threonate, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add Magnesium L-Threonate to our growing product portfolio and continue to carry through, Bajaj's commitment to deliver therapeutical products every year.
BHL intend to produce 12-15 tons of Magnesium L-Threonate in Q4 FY22 and 120 tons in FY23. We are expecting notable sales coming from the product. Addition of this new product in our existing product portfolio will further fuel the growth strategy for our formulation business. Addition of Magnesium LThreonate in our existing portfolio will further fuel the growth of our business and strengthen our position in the market."
